DarioHealth Corp (NASDAQ: DRIO) is a digital health company that operates a vertically integrated platform delivering chronic condition management across six condition areas, including diabetes, hypertension, weight management, GLP-1 support, musculoskeletal health, and behavioral health. Revenue comes from subscription-based SaaS fees sold through business-to-business channels (employers and health plans) and direct-to-consumer sales, with hardware devices such as blood glucose meters and blood pressure monitors bundled into the offering. The company sells to mid-to-large employers via a direct sales force and broker network, and to health plans on both a direct and claims-based billing basis. As of the 10-K filed March 19, 2026 (FY2025), the company disclosed limited revenue, negative cash flow, and a need for additional capital financing. DarioHealth was incorporated in Israel and operates subsidiaries including PsyInnovations Inc. and Twill, Inc. The company introduced DarioIQ, a proprietary AI layer, in Q4 FY2025 within its direct-to-consumer channel. The filing acknowledges a highly competitive digital health market and positions the company as a multi-condition, consolidated platform amid employer point-solution fatigue.

Revenue model

Subscription-based SaaS fees are the primary revenue stream, sold through B2B channels (employers and health plans) and direct-to-consumer. Hardware devices, including blood glucose meters and blood pressure monitors, are bundled with software and coaching services. Health plan contracts may be structured on a direct basis or through claims-based billing.

Products and services

Dario Health platform covering six chronic conditions: diabetes self-management (blood glucose monitor and app), hypertension (blood pressure monitor, cuff, and virtual coaching), weight management and GLP-1 support (app and virtual coaching), musculoskeletal health, and behavioral health (via Twill acquisition). DarioIQ is a proprietary AI conversational layer introduced in Q4 FY2025, initially deployed in direct-to-consumer offerings. DarioSHIFT is an internal AI operations toolset. Applications are distributed via the Apple App Store and Google Play Store.

Customers and end markets

Primary B2B customers are mid-to-large employers and health plans, including Medicare Advantage plans. Employers are reached through direct sales and broker or consultant intermediaries on a two-to-three-year RFP cycle. Health plans serve as both direct customers and a channel to employer groups. A direct-to-consumer channel also exists. End markets are U.S. working-age and insured populations with chronic conditions including diabetes, obesity, hypertension, and behavioral health needs.

Value-chain role

Vertically integrated platform provider: designs and owns proprietary hardware devices, develops and maintains software applications and AI layers, and delivers virtual coaching and clinical support. Sells through direct sales forces, brokers, consultants, and health plan partnerships. Operates as a vendor to employers and health plans rather than a care provider.

Geographic exposure

Primary operations in the United States. Subsidiary DarioHealth India Services Pvt. Ltd. operates in India. The company was founded in Israel and maintains operations there. Trademarks are registered across the U.S., EU, China, Canada, Australia, Brazil, Hong Kong, India, Japan, and via WIPO.

Source: SEC 10-K, filed 2026-03-19

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories ASENSUS SURGICAL, INC. Co-Diagnostics Inc Electromed Inc Fonar Corp Neuropace Inc PAVmed Inc KORU Medical Systems Inc